Click here for slides on this topic


Insulin

An anabolic hormone produced by the b-cells of the islets of Langerhans in the pancreas. Insulin is the major hormone that regulates plasma glucose concentrations by regulating rates of glucose production (suppressive effect) and utilization (stimulatory effect). Insulin also regulates lipid and protein metabolism. Relative or absolute insulin deficiency causes impaired glucose levels and diabetes.


The following content matched the glossary term: Insulin

NDEI.org Expert Commentary Silvio E. Inzucchi MD on Type 2 Diabetes Treatment Recommendations

Top

EXPERT COMMENTARY New Silvio E. Inzucchi, MD, on Phentermine Plus Topiramate for Weight Loss in Type 2 Diabetes   Silvio E. Inzucchi, MD  Weight loss remains a great challenge for our patients, especially those with type 2 diabetes. While lifestyle

AACE 2015 guidelines Glycemic Control Algorithm

Top

AACE’s glycemic control algorithm outlines pharmacologic treatment options for diabetes from the 2015 AACE guidelines 

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

Supporting a Family Member or Friend With Type 2 Diabetes

Top

Patient education handout that provides tips for offering support to a family member, friend, or loved one with type 2 diabetes.

Managing the Patient With Type 2 Diabetes and Heart Failure

Top

.style1 FONT FAMILY Arial, Helvetica, sans serif COLOR #004685

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

T195-03

Top

Patient education handout describing what causes type 2 diabetes; the effects of diabetes on patient quality of life; and diabetes treatments.

Association between intensification of metformin treatment with insulin vs sulfonylureas and CV events and all-cause mortality among patients with diabetes

Top

Roumie CL, Greevy RA, Grijalva CG, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA. 2014;311(22):2288-2296.

Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin + MDI insulin

Top

Rosenstock J, Jelaska A, Frappin G, et al; on behalf of the EMPA-REG MDI Trial Investigators. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014. DOI:10.2337/dc13-3055.

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: Insulin Slides Found: 416
Glyburide Monotherapy: Effect on Plasma Glucose and Insulin Levels
Sulfonylurea/Insulin Combination Therapy: Change in FPG and Insulin Dose
Adjunctive Metformin Therapy in Insulin-Treated Patients With Type 2 Diabetes and Suboptimal Glycemic Control
DIGAMI: Cumulative Mortality After Acute MI in Type 2 Diabetes: Low-Risk/No Previous Insulin
Insulin Resistance: Definitions
Insulin Resistance: Inherited and Acquired Influences
Aerobic Exercise Improves Insulin Sensitivity
Ethnicity vs Race
Prevalence of the Insulin Resistance Syndrome (NCEP) in the US Population
Family History of Diabetes and Risk for Insulin Resistance in Mexican Amercians
Risk Factors for Conversion to Diabetes in Mexican Americans
Association Between Insulin Sensitivity and Physical Exercise The IRAS Study
Treating Insulin Resistance Reduces Incidence of Type 2 Diabetes
Treating Insulin Resistance Preserves b-Cell Function
Hypertension and Glucose Tolerance in Four Ethnic Groups
Opportunities and Challenges for Care Extended Family Roles
Myths About Diabetes and Hispanic Patients
Addressing Sociocultural Issues
Results From a Culturally Sensitive Behavioral Management Program
Type 2 Diabetes Prevention Studies
Energy Balance: Intake vs Expenditure
Energy Balance: Afferent and Efferent Signals
Effect of Leptin on Weight Loss: Dose-Ranging Study
Increased Fructose Consumption and the Rise in Obesity
Effects of Antidiabetic Agents on Weight
Thiazolidinediones and Adipose Tissue Redistribution
Assessing Risk for Morbidity and Mortality: Comorbidities and Other Risk Factors
Effect of the Atkins Diet on Weight, Lipids, and Insulin
Low-Carbohydrate Diet vs Low-Fat Diet
Effect of Aerobic Exercise on Insulin Resistance
Adiponectin and CRP Levels in Healthy Obese Women
Relationship Between Flow-Mediated Brachial Artery Dilation and Weight Loss After Lifestyle Modification
Changes in Flow-Mediated Brachial Artery Dilation After 6 Months of Lifestyle Modification
Effect of Diet and Exercise on Adipokines
Effect of Diet and Exercise on Inflammatory Markers
Effect of Phentermine on Weight Loss in Obese Patients With Type 1 or Type 2 Diabetes
Effect of Sibutramine, Orlistat, and Metformin on Risk Factors for Type 2 Diabetes
Effect of Bariatric Surgery on Acute Insulin Response
Effect of Roux-en-Y Bypass on Treatment of Type 2 Diabetes
Insulin Resistance: Definitions
Association Between Small, Dense LDL and Insulin Resistance
Glyburide Monotherapy: Effect on Plasma Glucose and Insulin Levels
Sulfonylurea/Insulin Combination Therapy: Change in FPG and Insulin Dose
Adjunctive Metformin Therapy in Insulin-Treated Patients With Type 2 Diabetes and Suboptimal Glycemic Control
Insulin Resistance: Inherited and Acquired Influences
Aerobic Exercise Improves Insulin Sensitivity
Effect of Pioglitazone on Insulin Resistance: HOMA-IR
UKPDS Results of Intensive Therapy: Sulfonylurea and Insulin
Effect of Early Thiazolidinedione Therapy on A1C Levels
Effect of Early Thiazolidinedione Therapy on C-Peptide Levels
Effect of Early Thiazolidinedione Therapy on Diabetes Onset
IRAS: Number of CVD Risk Factors and Conversion to Type 2 Diabetes
Gender Differences Influence Impact of Type 2 Diabetes on CHD Risk
ARIC: Association Between MetS Components and CHD Risk
CARDIA: Fast-Food Frequency and Insulin Resistance
Pioglitazone Decreases Carotid IMT Independent of Glycemic Control in Patients With Type 2 Diabetes
Exenatide: Clinical Pharmacology
Pramlintide Adjunctive Therapy Offers Long-Term Glycemic Control
Effect of Pramlintide Adjunctive Therapy on Weight in Patients With Type 2 Diabetes
Metabolic and Vascular Actions of PPAR-alpha and PPAR-gamma Agonists
Adverse Events Associated With Thiazolidinedione Treatment
DIGAMI 2: Cumulative Mortality After Acute MI in Type 2 Diabetes
PROactive: Objective/Endpoints
Prevalence of IFG in Nondiabetic US Adolescents (Aged 12–19 Yrs)
Waist Circumference, TG Levels Predict Future MetS in 18- to 19-Yr-Old Females
Comparison of Diabetes Rates Across PIPOD and TRIPOD
Glucagon-Like Peptide-1
Insulin and GLP-1 Responses to Meals
Effect of GLP-1 on the Beta-Cell
GLP-1 Infusion Improves Beta-Cell Insulin Secretion
GLP-1 and First-Phase Insulin Secretion
Exenatide: Effect on the Beta-Cell
Normal Relationship Between Insulin Sensitivity and Response: The Disposition Index
Regulation of Insulin Secretion
Beta-Cell Adaptation to Insulin Resistance: Longitudinal Data in Normal Women
Plasticity of Islets: Experimental Increase in Beta-Cell Mass in Response to IR
Neogenesis May Contribute to Increased Islet Mass in Obese Humans
Hypothetical Relationships Determine Categories of Glucose Tolerance
Hypothetical Outcomes of Interventions to Treat Type 2 Diabetes
Hypothetical Outcomes of Interventions to Prevent Type 2 Diabetes
Type 2 Diabetes: Pathogenesis in a Nutshell
Patients Achieving ADA A1C Goal on 18-Wk Sitagliptin Monotherapy
18-Wk Sitagliptin Monotherapy Improves b-Cell Function
Type 2 Diabetes: Pathogenesis in a Nutshell (cont.)
Decreased beta-Cell Function in Groups With Diabetes and at High Risk
Short-term beta-Cell Adaptation: Response to Pregnancy
Declining beta-Cell Function: Best Correlation of Progression
Loss of beta-Cell Function in People Who Develop Type 2 Diabetes: Longitudinal Data
Functional Defects in beta-Cells in the Development of Diabetes
UKPDS: Progressive Deterioration in Glycemic Control Over Time
Early Nutrient-Induced Insulin Secretion
Fasting Plasma Glucose and the Acute Insulin Response
Acute Insulin Response to Glucose
Acute Insulin Response to Arginine
Decreases in Insulin Response
Altered beta-Cell Mass and Function in Islets From Subjects With Type 2 Diabetes
Role of Islet Amyloid in beta-Cell Dysfunction
Tools to Assess beta-Cell Health and Function
24-Week Sitagliptin Monotherapy Improves Glycemic Control in Patients With Type 2 Diabetes
Sitagliptin Enhances Glycemic Control, beta-Cell Function in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Improves Glycemic Control in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
ADOPT: Cumulative Incidence of Monotherapy Failure at 5 Years
ADOPT: Achievement of A1C Levels <7%
Vildagliptin + Pioglitazone Increases Beta-Cell Insulin Secretory Rate
Thiazolidinediones vs Insulin: Comparison of Diabetes-Related Healthcare Utilization and Costs Over 12 Months
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Sitagliptin on 2-Hour Post-Meal Plasma Glucose in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Sitagliptin Monotherapy on 2-Hour Postprandial Glucose in Patients With Type 2 Diabetes
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Effect of Exenatide + TZD on Body Weight in Patients With Type 2 Diabetes
Effect of Sitagliptin + Metformin on FPG in Patients with Type 2 Diabetes
RECORD: Study Design
Effect of Sitagliptin + Metformin on B-Cell Function at 24 Weeks
CALM: Renoprotection With Candesartan vs Lisinopril in Type 2 Diabetes
IRAS: CVD Risk Factors Are Also Risk Factors for Type 2 Diabetes
Pioglitazone Reduces the Risk of Hospitalization for AMI
Frequent Adverse Events in Diabetic Patients Treated With GLP-1 Analogues
Hypoglycemia Risk Factors in Elderly Patients With Type 2 Diabetes
Effect of Vildagliptin Added to Glimepiride on ß-Cell Function in Patients With Type 2 Diabetes
ACCORD: Study Design
ADVANCE: Study Design
ADVANCE Trial: Combined Major Macrovascular and Microvascular Events
ADVANCE Trial: Risk for Major Macrovascular and Microvascular Events
ACCORD Trial: Intensive Blood Glucose Control in Patients With Type 2 Diabetes
ACCORD Trial: CV Events With Intensive Blood Glucose Control
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Any Diabetes Endpoint
UKPDS: Intensive Metformin vs Conventional Therapy: Diabetes Endpoints
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Myocardial Infarction
UKPDS: Intensive Metformin vs Conventional Therapy: Myocardial Infarction
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Death From Any Cause
UKPDS: Intensive Metformin vs Conventional Therapy: Death From Any Cause
Alogliptin Added to Insulin: A1C
Type 2 Diabetes Therapy and Cardiovascular Events: Comparing VADT With Other Trials
IRAS: Risk of Type 2 Diabetes Based on Food-Pattern Score at Baseline
IRAS: Risk of Type 2 Diabetes by Food-Pattern Score and Obesity Status
HEART2D: Primary Outcome Vs Days in Trial by Treatment Strategy
HEART2D Trial: A1C Values at Each Visit for 60 Months
Prevalence of IFG, IGT, and Prediabetes According to a Combination of Central Obesity and Hyperinsulinemia
Efficacy of Pioglitazone Plus Sibutramine in Metformin-Intolerant vs Metformin-Tolerant Obese Subjects With Type 2 Diabetes
Survival Functions for the Secondary Macrovascular Endpoint
Impact of Higher Heart Rate on Development of Cardiometabolic Risk Factors After 20 Years
Survival Functions for the Primary Macrovascular Endpoint
Improved Glycemic Control When Adding Metformin to Insulin Therapy
Indian Diabetes Prevention Programme-2: Study Design
Indian Diabetes Prevention Programme-2: Results
Whitehall II: Design
Whitehall II: Fasting Glucose From Baseline to 13 Years
Whitehall II: 2-Hour Postload Glucose From Baseline to 13 Years
Whitehall II: HOMA Insulin Sensitivity Trajectory Before Diagnosis of Diabetes or End of Follow-Up
Whitehall II: HOMA b-Cell Function Trajectory Before Diagnosis of Diabetes or End of Follow-Up
Whitehall II: Conclusion
RECORD: Study Design
RECORD: CV Death and Hospitalization
RECORD: Time to Primary Endpoint
RECORD: Bone Fracture Rates in Upper and Distal Lower Limbs
RECORD: Conclusion
Whitehall II: 2-Hour Postload Glucose From Baseline to 13 Years
VADT: Primary Endpoint
BP and Type 2 Diabetes Risk in African Americans and Whites: Results
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Design
Effect of Liraglutide on Cardiovascular Disease Risk Factors: Results
Effect of Liraglutide and Insulin on Cardiovascular Disease Risk Factors
Liraglutide Effect on Cardiovascular Disease: Results Among Patients Switched from Exenatide
San Luigi Gonzaga Diabetes Study: Design
San Luigi Gonzaga Diabetes Study: Results
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Design
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Change in A1C from Baseline to Week 52
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Additional Results
STAMPEDE: Design
STAMPEDE Results: Primary Endpoint (A1C ≤6%) at 12 Months
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Results
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Additional Results
ORIGIN Trial: Design
ORIGIN Trial: Baseline Characteristics (1 of 2)
ORIGIN Trial: Baseline Characteristics (2 of 2)
ORIGIN Trial: Results
TODAY Study: Design
TODAY Study: Eligibility Criteria and Run-in Period
TODAY Study: Baseline Characteristics
TODAY Study: Primary Outcome—Loss of Glycemic Control
TINSAL-T2D Trial: Eligibility Criteria and Study Protocol
ORIGIN Glargine Trial: Design
ORIGIN Glargine Trial: Primary and Secondary Outcomes
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
ORIGIN Glargine Trial: Baseline Characteristics (1 of 2)
ORIGIN Glargine Trial: Baseline Characteristics (2 of 2)
ORIGIN Glargine Trial: Insulin Use During Trial
ORIGIN Glargine Trial: A1C, FPG During Trial
ORIGIN Glargine Trial: First Coprimary Composite CV Outcome—CV Death, Nonfatal MI, or Nonfatal Stroke
ORIGIN Glargine Trial: Second Coprimary Composite CV Outcome—CV Death, Nonfatal MI, Nonfatal Stroke, Revascularization, or Hospitalized Heart Failure
ORIGIN Glargine Trial: Secondary Outcomes
ORIGIN Glargine Trial: Secondary Outcome—Cancer Incidence
ORIGIN Glargine Trial: Hypoglycemia
ORIGIN Glargine Trial: Weight Change
ORIGIN Glargine Trial: Conclusions
ORIGIN Omega-3 Fatty Acid Trial: Design
ORIGIN Omega-3 Fatty Acid Trial: Primary and Secondary Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Additional Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (1 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (2 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Primary Outcome—CV Death
ORIGIN Omega-3 Fatty Acid Trial: Secondary Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Mean Change in Lipids
ORIGIN Omega-3 Fatty Acid Trial: Conclusions
DPPOS Substudy: NGR Predictors During DPPOS
DPPOS Substudy: Additional Outcomes
EASIE Trial: Design
EASIE Trial: Study and Enrollment Profile
EASIE Trial: Efficacy Population Primary Outcome at Week 24—Change in A1C from Baseline
EASIE Trial: Efficacy Population A1C <7.0% and <6.5% Week 24
EASIE Trial: Safety Population Hypoglycemia and Adverse Events
ORIGIN: Design
Health Consequences of Obesity
Long-term Weight Loss After Roux-en-Y Gastric Bypass
Long-term Change in BMI After Roux-en-Y Gastric Bypass
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Glycemic Control Results
AusDiab Substudy: Design
SOS Analysis: Interaction Between Risk Factors and Treatment
Pooled Analysis: Mortality Among Normal and Overweight/Obese Subjects with Diabetes
Pooled Analysis: Mortality Rates Among Normal and Overweight/Obese Subjects with Diabetes
Look AHEAD: 1-Year Interim Results
Look AHEAD: Design
Look AHEAD at 4 Years: Weight Reduction By Subgroup, Insulin Use
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Key Facts on Prevalence, Epidemiology
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Considerations for Individualizing Treatment (2 of 2)
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Recommendations for Care and Treatment (2 of 3)
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Recommendations for Care and Treatment (3 of 3)
FIN-D2D: Statin Use at Baseline and Glucose Values at 1 Year
Guidelines for Children and Adolescents With Type 2 Diabetes: Insulin Therapy
Guidelines for Children and Adolescents With Type 2 Diabetes: Lifestyle Changes, Metformin for All
Guidelines for Children and Adolescents With Type 2 Diabetes: Blood Glucose Testing (1 of 2)
Guidelines for Children and Adolescents With Type 2 Diabetes: Blood Glucose Testing (2 of 2)
Look AHEAD: Continuous, Sustained Type 2 Diabetes Remission
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Background
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Design
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Primary Endpoint
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Mean A1C Change
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: A1C Target at Endpoint
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Mean Body Weight Change
Weight Gain in ACCORD By Type 2 Diabetes Treatment Allocation
Medication Use and Weight Gain in ACCORD
Inpatient Glycemic Control: Is There an Optimal Insulin Strategy?
Basal Plus Trial: Design and Randomization
Basal Plus Trial: Improvement in Mean Daily BG
Basal Plus Trial: Target Glucose Levels
Basal Plus Trial: Hypoglycemia
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Design
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Study Protocol and Meals
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Results for Glucose and Hormones
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Indices of Insulin Action
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Summary of Findings
ADA/Endocrine Society: Definition of Hypoglycemia in Diabetes
ADA/Endocrine Society: Strategies for Preventing Hypoglycemia (1 of 2)
ADA/Endocrine Society: Strategies for Preventing Hypoglycemia (2 of 2)
ADA/Endocrine Society: Minimizing Hypoglycemia Risks in the Elderly
ORIGIN-GRACE: Design
ORIGIN-GRACE: Primary and Secondary Outcomes
ORIGIN-GRACE: Select Baseline Characteristics
ORIGIN-GRACE: No Difference in Annualized Change in Max CIMT for 12 Carotid Artery Segments with Glargine or Omega-3 Fatty Acid
ORIGIN-GRACE: Glargine, Not Omega-3 Fatty Acid, Improves Annualized Change in Max CIMT
ORIGIN-GRACE: No Difference in Annualized Change in Max Far Wall CIMT for Glargine or Omega-3 Fatty Acid
ORIGIN-GRACE: Major Cardiovascular Events
ORIGIN-GRACE: Summary of Findings
ORIGIN-GRACE: Eligibility Criteria and Trial Profile
ESH/ESC Hypertension Guidelines: Hypertension Treatment for People With Metabolic Syndrome
Look AHEAD: Lifestyle Changes Improve Glycemic Control, CV Risk Factors
ACP Guidelines: Inpatient Hyperglycemia Management with IIT
ACP Guidelines: Inpatient Hyperglycemia Management with IIT
Efficacy of Twice-Daily Exenatide Added to Basal Insulin for A1C Reduction: Design
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo : A1C Reduction at 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Target A1C Levels at 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Body Weight 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Hypoglycemia at 30 Wks
Twice-Daily Exenatide Vs Placebo Added to Basal Insulin: Adverse Events
ACCORD: Factors Associated with Increased Hypoglycemia Risk in Intensive and Standard Treatment Arms
STAMPEDE Metabolic Substudy: A1C Improvement in All Groups at 24 Months
STAMPEDE Metabolic Substudy: Greater Increases in Insulin Sensitivity, Beta-Cell Function with Gastric Bypass
EXAMINE: No Increase in CV Events with Alogliptin Primary Endpoint
EXAMINE: No Increase in CV Events with Alogliptin Secondary Endpoint
EXAMINE: Significantly Greater A1C Change from Baseline with Alogliptin Vs Placebo
EXAMINE: Adverse Events
EXAMINE: Design
ADA Nutrition Guidelines: Nutrition Therapy
ADA Nutrition Guidelines: Carbohydrates
ADA Nutrition Guidelines: Alcohol
ADA Nutrition Guidelines: Priorities for Nutrition Management By Medication
ADA Nutrition Guidelines: Priorities for Nutrition Management for Type 1 Diabetes and Insulin-Requiring Type 2 Diabetes
Liraglutide 12-Week Treatment: Effect on Glycemic Control
LEAD-3: Liraglutide vs Glimepiride: A1C Level
LEAD-3: Liraglutide vs Glimepiride in Drug-Naïve Patients: A1C
LEAD-3: Liraglutide vs Glimepiride in Previously on Oral Agents: A1
Liraglutide Improves ß-Cell Function and Insulin Secretion During Hyperglycemia in Patients With Type 2 Diabetes
Liraglutide Reduces A1C Irrespective of Baseline A1C
Liraglutide Enhances Glucose-Dependent Insulin Secretion
AleCardio: Design
STAMPEDE: A1C Less Than or Equal to 6.0 Percent at 3 Yrs With Bariatric Surgery Vs Medical Therapy
US Trends in Type 2 Diabetes Treatment, 1997-2012: Type of Treatment Used, Visit with 2+ Compounds in 2012
US Trends in Type 2 Diabetes Treatment, 1997-2012: Insulin Use
SEQUEL Subanalysis: Annualized Incidence of Type 2 Diabetes at Wk 108
Type 2 Diabetes Treatment Intensification Micro- Macrovascular | NDEI
Type 2 Diabetes Treatment Intensification Acute MI | NDEI
Type 2 Diabetes Treatment Intensification Albuminuria | NDEI
Type 2 Diabetes Treatment Intensification eGFR Kidney | NDEI
Incretin Therapies Vs Sulfonylureas Pancreatitis Type 2 Diabetes | NDEI
IDF 2012 Type 2 Diabetes Guidelines Glucose Monitoring | NDEI
IDF 2012 Type 2 Diabetes Guidelines Glucose Treatment Management | NDEI
IDF 2012 Type 2 Diabetes Guidelines Insulin Therapy | NDEI
IDF 2012 Type 2 Diabetes Guidelines Blood Pressure Targets | NDEI
IDF 2012 Type 2 Diabetes Guidelines Blood Pressure Treatment | NDEI
IDF Type 2 Diabetes Treatment Guidelines Older Adults Elderly | NDEI
IDF Type 2 Diabetes Guidelines In-Patient Critically Ill | NDEI
Emplagliflozin SGLT 2 A1C EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 Weight Loss EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 Insulin EMPA-REG MDI Study | NDEI
Empagliflozin SGLT2 Adverse Events EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 EMPA-REG MDI Study | NDEI
Diabetes Cognitive Dysfunction | NDEI
Type 2 Diabetes Alzheimer Disease | NDEI
Type 2 Diabetes Treatments Used for Alzheimer Disease? | NDEI
Insulin Sulfonlyrea Added to Metformin CVD Mortality | NDEI
Metformin + Insulin or Sulfonylurea CVD Mortality | NDEI
Metformin + Insulin or Sulfonylurea CVD Mortality Design | NDEI
Diabetes Pregnancy Guidelines Insulin Therapy | NDEI
Diabetes Pregnancy Guidelines Noninsulin Therapy | NDEI
Diabetes Pregnancy Guidelines Preconception Insulin | NDEI
Statin Potency New-Onset Diabetes Risk | NDEI
Statin Potency & Type 2 Diabetes Risk | NDEI
High-Potency Statins & Increased Diabetes Risk Secondary Prevention | NDEI
SGLT2 Inhibitors Type 2 Diabetes Treatment Slides | NDEI
Sulfonylurea Treatment All-Cause CV Mortality Type 2 Diabetes Treatment | NDEI
DPP-4 Inhibitors Type 2 Diabetes Treatment | NDEI
GLP-1 Receptor Agonists Type 2 Diabetes Treatment | NDEI
Basal Insulin Glycemic Control A1C Type 2 Diabetes | NDEI
ADVANCE-ON Type 2 Diabetes Study Baseline Characteristics Slide | NDEI
Diabetes & Aging Study Type 2 Diabetes Remission Linked With Diabetes Duration | NDEI
SGLT2 Dapagliflozin + Insulin Type 1 Diabetes Treatment Slide | NDEI
Adverse Events Dapagliflozin As Insulin Adjunct in Type 1 Diabetes | NDEI
Dapagliflozin Pharmacokinetics in Type 1 Diabetes SGLT 2 | NDEI
Average Daily Glucose Changes & Insulin Use Dapagliflozin Type 1 Diabetes | NDEI
Dapagliflozin Type 1 Diabetes SGLT2 Data Review | NDEI
BLOOM-DM Lorcaserin Glycemic Effect Type 2 Diabetes | NDEI
Teen-LABS CVD Risk in Adolescents Undergoing Bariatric Surgery | NDEI
Safety Bariatric Surgery for BMI <35 at 1 Year
ACCORD-MIND Hypoglycemia Age, Intensive Therapy, Diabetes Duration | NDEI
EMPA-REG Blood Pressure Lowering With Empagliflozin Type 2 Diabetes Hypertension | NDEI
Type 1 Diabetes Classification & Diagnosis
ADA Type 1 Diabetes Guidelines Diagnosis Clues Slide | NDEI
ADA Type 1 Diabetes Guidelines Nutrition Therapy | NDEI Slides
ADA Type 1 Diabetes Guidelines Physical Activity | NDEI Diabetes Slides
Glucose Monitoring SMBG CGM ADA Type 1 Diabetes Guidelines | NDEI
Insulin Therapy ADA Type 1 Diabetes Guidelines | NDEI Slides
Noninsulin Therapies ADA Type 1 Diabetes Guidelines | NDEI Slides
Hypoglycemia Management ADA Type 1 Diabetes Guidelines | NDEI
Diabetic Ketoacidosis Management ADA Type 1 Diabetes Guidelines | NDEI
Inpatient Outpatient Management ADA Type 1 Diabetes Guidelines | NDEI
Child Care Recommendations ADA Type 1 Diabetes Guidelines | NDEI
ADA EASD Treatment Algorithm Type 2 Diabetes | NDEI
ADA EASD Position Statement Insulin Use in Type 2 Diabetes | NDEI
DURATION-3 & LEAD-5 Post-Hoc Analysis Insulin Type 2 Diabetes PPT | NDEI
A1C Reduction GLP-1 RAs & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Similar A1C Goal Achievement GLP-1 RA & Glargine DURATION-3 & LEAD-5 | NDEI
Weight Loss With GLP-1 RA & Increase With Glargine in DURATION-3 & LEAD-5 | NDEI
Hypoglycemia With GLP-1 RA & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Combination GLP-1 RA & Basal Insulin Treatment Type 2 Diabetes | NDEI
Hypoglycemia & Weight After Treatment With GLP-1 RA + Basal Insulin | NDEI
Endocrine Society Obesity Guidelines Treating Type 2 Diabetes PPT | NDEI
AACE 2015 Diabetes Guidelines Algorithm Intensifying Insulin PPT | NDEI
AACE 2015 Diabetes Guidelines Lifestyle Changes Diet Exercise PPT | NDEI
AACE 2015 Diabetes Guidelines Treating Hyperglycemia in the Hospital | NDEI
AACE 2015 Diabetes Guidelines Glucose Monitoring CGM SMBG PPT | NDEI
AACE 2015 Guidelines Treating Gestational Diabetes GDM PPT | NDEI
TECOS Sitagliptin Cardiovascular Safety High-Risk Type 2 Diabetes DPP-4 | NDEI
TECOS Cardiovascular Outcomes Sitagliptin DPP-4 | NDEI
TECOS Heart Failure Sitaliptin DPP-4 CV Safety | NDEI
TECOS Sitagliptin DPP-4 Inhibitor Pancreatitis Hypoglycemia | NDEI
TECOS Sitagliptin A1C Efficacy DPP-4 Inhibitor CV Safety | NDEI
Diabetes Medications & Weight AHA ADA CVD Prevention Guidelines | NDEI
A1C Targets AHA ADA Guidelines Type 2 Diabetes CVD Prevention | NDEI
Hypoglycemia & CVD Risk Type 2 Diabetes AHA ACC Guidelines PPT | NDEI
Sitagliptin Not Associated With Heart Failure in TECOS Type 2 Diabetes | NDEI
Study Examines Overall Safety of Bariatric (Metabolic/Diabetes) Surgery
Insulin Glargine Neutral on CV Outcomes & Cancer Diabetes ORIGIN | NDEI
Neutral Omega-3 Effect on CV Outcomes in ORIGIN Diabetes | NDEI
Insulin Glargine A1C Reduction Type 2 Diabetes PPT | NDEI
AWARD-2: Once-Weekly Dulaglutide Vs Insulin Glargine Type 2 Diabetes | NDEI
Lower A1C With Dulaglutide Vs Insulin Glargine AWARD-2 Results | NDEI
Saxagliptin Not Associated With Fractures in SAVOR-TIMI 53 Analysis | NDEI
Safety of Dulaglutide & Insulin Glargine Pancreatitis AWARD-2 | NDEI
Continuous Glucose Monitoring (CGM) Insulin Type 2 Diabetes ADA Guidelines | NDEI
Type 1 Diabetes Treatment Options ADA Guidelines 2016 | NDEI PPT
Type 2 Diabetes Treatment Algorithm ADA Guidelines 2016 | NDEI PPT
Strategies for Insulin Use in Type 2 Diabetes ADA Guidelines | NDEI PPT
Glycemic Targets for Children With Type 1 Diabetes ADA Guidelines | NDEI
ADA Diabetes Care Guidelines for Hospitalized Patients | NDEI PPT
Glycemic Targets for Critically Ill Patients ADA Guidelines | NDEI PPT
ADA Glycemic Targets for Non-Critically Ill Patients With Diabetes | NDEI
Key Points from TECOS Subanalysis Sitagliptin DPP-4 | NDEI PPT
JUPITER Secondary Analysis Assesses Statin Use & Diabetes Risk | NDEI
JUPITER High-Intensity Rosuvastatin & Lipoprotein Particles | NDEI
JUPITER Effect of High-Intensity Rosuvastatin on Lipoproteins Diabetes | NDEI
JUPITER Rosuvastatin & Incident Type 2 Diabetes | NDEI
JUPITER Insulin Resistance Associated With Risk Factors | NDEI
JUPITER Incident Diabetes Associated With More Risk Factors Rosuvastatin | NDEI
AWARD-2 Design Dulaglutide Vs Insulin Glargine Type 2 Diabetes | PPT
AWARD-2: Lower A1C With Dulaglutide Vs Insulin Glargine Type 2 Diabetes | NDEI
AWARD-2 Similar Adverse Events With Dulaglutide & Insulin Glargine Type 2 Diabetes | NDEI
ORIGINALE No Increase in CV Events or Cancer with Insulin Glargine Diabetes | NDEI
ORIGINALE No Effect of Omega-3 Fatty Acids on CV Outcomes | NDEI
ORIGINALE A1C Reduction With Insulin Glargine Type 2 Diabetes | NDEI
NLA Cholesterol Guidelines Metabolic Syndrome Criteria | CCMD
Type 2 Diabetes Treatment Algorithm for Metabolic (Bariatric) Surgery | NDEI
IRIS Design Pioglitazone Effect on Cerebrovascular Disease Stroke PPT | NDEI
IRIS Pioglitazone Lowers Risk for Stroke and TIA Vs Placebo PPT | NDEI
IRIS Pioglitazone Lowers Rate of Progression to Diabetes Vs Placebo | NDEI
IRIS Safety of Pioglitazone Vs Placebo After Stroke or TIA PPT | NDEI